Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Verseon starts dosing in trial of VE-1902 to treat CAD

Micrograph of a coronary artery with the most common form of coronary artery disease (atherosclerosis). Credit: Nephron.

  • Verseon

Go Top